HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine

Favorable performance of DTG compared with other first-line ART options in sustaining VS supports continued roll-out of DTG-based regimens. High overall incidence of viral rebound, including on DTG-based regimens, calls for targeted evidence-based adherence support interventions and improved viral load and drug resistance monitoring, especially among high-risk populations.

Authors

Institutions

Publication Details

Journal
JAIDS Journal of Acquired Immune Deficiency Syndromes
Published
2025-04-07
DOI
https://doi.org/10.1097/qai.0000000000003676
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine

Kostyantyn Dumchev, Nancy Puttkammer, Serhii Riabokon, Kevin Conroy et al.
1 links
JAIDS Journal of Acquired Immune Deficiency Syndromes
HIV/AIDS drug development and treatment
article

HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine

Kostyantyn Dumchev, Nancy Puttkammer, Serhii Riabokon, Kevin Conroy, Olga Morozova, Myroslava Germanovich, Yaroslav Zelinskyi
article en

Abstract

Favorable performance of DTG compared with other first-line ART options in sustaining VS supports continued roll-out of DTG-based regimens. High overall incidence of viral rebound, including on DTG-based regimens, calls for targeted evidence-based adherence support interventions and improved viral load and drug resistance monitoring, especially among high-risk populations.

JAIDS Journal of Acquired Immune Deficiency SyndromesVol. 99(4)
Washington State Department of Health (US), Ministry of Defence (GB), Ministry of National Defense (KR), Chicago Department of Public Health (US), University of Washington (US), Office of the National Coordinator for Health Information Technology (US), University of Chicago (US), Ministry of Health (UA), Ukrainian Institute of Public Health Policy (UA), Ministry of Defense (IL)
Good health and well-being
Openalex Percentile: Top 90%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine — Kostyantyn Dumchev, Nancy Puttkammer, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes (2025) | TGRS Research Map | TGRS